Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study

The Lancet Oncology

Volumn 17, Issue 4, 2016, Pages 532-538

  Italiano, Antoine ^a   Di Mauro, Ilaria ^b,c   Rapp, Jocelyn ^b,c   Pierron, Gaëlle ^d   Auger, Nathalie ^e   Alberti, Laurent ^f   Chibon, Frédéric ^g   Escande, Fabienne ^h   Voegeli, Anne Claire ⁱ   Ghnassia, Jean Pierre ^j   Keslair, Frédérique ^b,c   Laé, Marick ^d   Ranchère Vince, Dominique ^f   Terrier, Philippe ^e   Baffert, Sandrine ^d   Coindre, Jean Michel ^g   Pedeutour, Florence ^b,c  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITY HOSPITAL OF NICE   (France)

^c UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^d INSTITUT CURIE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE LÉON BÉRARD   (France)

^g UNIVERSITÉ DE BORDEAUX   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^j Paul Strauss Centre   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; DEDIFFERENTIATED LIPOSARCOMA; DERMATOFIBROSARCOMA PROTUBERANS; DIFFERENTIAL DIAGNOSIS; EWING SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MULTICENTER STUDY; MYXOSARCOMA; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SARCOMA; SYNOVIAL SARCOMA; TUMOR BIOPSY; VERY ELDERLY; BIOSYNTHESIS; CLASSIFICATION; CLINICAL TRIAL; DERMATOFIBROSARCOMA; GENE EXPRESSION REGULATION; GENETICS; LIPOSARCOMA; MIDDLE AGED; MOLECULAR PATHOLOGY; PATHOLOGY; PROCEDURES; PROGNOSIS;

TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; COMPARATIVE GENOMIC HYBRIDIZATION; DERMATOFIBROSARCOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PATHOLOGY, MOLECULAR; PROGNOSIS; SARCOMA;

EID: 84959911583     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00583-5     Document Type: Article

References (30)

1. 1 Fletcher, CDM, Unni, KK, Mertens, F, Pathology and genetics of tumours of soft tissue and bone. World Health Organization, 2013, IARC Press, Lyon.
2. 2 Arbiser, ZK, Folpe, AL, Weiss, SW, Consultative (expert) second opinions in soft tissue pathology. Analysis of problem-prone diagnostic situations. Am J Clin Pathol 116 (2001), 473–476.
3. 3 Ray-Coquard, I, Montesco, MC, Coindre, JM, et al., the Conticanet group. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 23 (2012), 2442–2449.
4. 4 Thway, K, Fisher, C, Histopathological diagnostic discrepancies in soft tissue tumours referred to a specialist centre. Sarcoma, 2009, 2009, 741975.
5. 5 Delattre, O, Zucman, J, Melot, T, et al. The Ewing family of tumors—a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 331 (1994), 294–299.
6. 6 Coindre, JM, Pelmus, M, Hostein, I, Lussan, C, Bui, BN, Guillou, L, Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer 98 (2003), 2700–2707.
7. 7 Guillou, L, Coindre, J, Gallagher, G, et al. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives. Hum Pathol 32 (2001), 105–112.
8. 8 Hostein, I, Andraud-Fregeville, M, Guillou, L, et al. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens. Cancer 101 (2004), 2817–2824.
9. 9 Williamson, D, Missiaglia, E, de Reyniès, A, et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 28 (2010), 2151–2158.
10. 10 Coindre, JM, Hostein, I, Terrier, P, et al. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group. Cancer 107 (2006), 1055–1064.
11. 11 de Vreeze, RSA, de Jong, D, Nederlof, PM, et al. Added value of molecular biological analysis in diagnosis and clinical management of liposarcoma: a 30-year single-institution experience. Ann Surg Oncol 17 (2010), 686–693.
12. 12 Sirvent, N, Coindre, JM, Maire, G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffin-embedded tumor samples: utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol 31 (2007), 1476–1489.
13. 13 Weaver, J, Downs-Kelly, E, Goldblum, JR, et al. Fluorescence in situ hybridization for MDM2 gene amplification as a diagnostic tool in lipomatous neoplasms. Mod Pathol 21 (2008), 943–949.
14. 14 Neuville, A, Ranchère-Vince, D, Dei Tos, AP, et al. Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. Am J Surg Pathol 37 (2013), 1259–1268.
15. 15 Karanian, M, Pérot, G, Coindre, JM, Chibon, F, Pedeutour, F, Neuville, A, Fluorescence in situ hybridization analysis is a helpful test for the diagnosis of dermatofibrosarcoma protuberans. Mod Pathol 28 (2015), 230–237.
16. 16 ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:suppl 3 (2014), iii102–iii112.
17. 17 https://clinicaltrials.gov/ct2/show/NCT00847691 (accessed Aug 17, 2015).
18. 18 Fletcher, CDM, Unni, KK, Mertens, F, World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone, 2002, IARC Press, Lyon.
19. 19 Blay, JY, Pápai, Z, Tolcher, AW, et al. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16 (2015), 531–540.
20. 20 von Mehren, M, Randall, RL, Benjamin, RS, et al., the National Comprehensive Cancer Network. Soft tissue sarcoma, version 2. 2014. J Natl Compr Canc Netw 12 (2014), 473–483.
21. 21 Kroep, JR, Ouali, M, Gelderblom, H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol 22 (2011), 207–214.
22. 22 Coindre, JM, Hostein, I, Maire, G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 203 (2004), 822–830.
23. 23 Le Guellec, S, Chibon, F, Ouali, M, et al. Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?. Am J Surg Pathol 38 (2014), 293–304.
24. 24 Italiano, A, Bianchini, L, Keslair, F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer 122 (2008), 2233–2241.
25. 25 Ficher, C, The diversity of soft tissue tumours with EWSR1 gene rearrangements: a review. Histopathology 64 (2014), 134–150.
26. 26 Antonescu, CR, Dal Cin, P, Promiscuous genes involved in recurrent chromosomal translocations in soft tissue tumours. Pathology 46 (2014), 105–112.
27. 27 Argani, P, Antonescu, CR, Illei, PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 159 (2001), 179–192.
28. 28 Laé, M, Fréneaux, P, Sastre-Garau, X, Chouchane, O, Sigal-Zafrani, B, Vincent-Salomon, A, Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum. Mod Pathol 22 (2009), 291–298.
29. 29 Patel, SP, Schwaederle, M, Daniels, GA, et al. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget 6 (2015), 32602–32609.
30. 30 Italiano, A, Cardot, N, Dupré, F, et al. Gains and complex rearrangements of the 12q13-15 chromosomal region in ordinary lipomas: the “missing link” between lipomas and liposarcomas?. Int J Cancer 121 (2007), 308–315.